Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Valter Gattei, Luca Laurenti et al.|Leukemia|2020Cited by 24
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and RituximabMassimo Gentile, Fortunato Morabito, Gianluigi Reda et al.|Blood|2019Cited by 1
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0